Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Citius Oncology ( (CTOR) ) just unveiled an announcement.
On June 17, 2025, Citius Oncology announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved treatment for relapsed or refractory cutaneous T-cell lymphoma, are nearing completion. The company has secured its supply chain and is finalizing distribution agreements to ensure broad access across the U.S. This launch is expected in the second half of 2025 and is seen as a significant milestone for the company and the CTCL community, with early interest from oncology centers and strategic partnerships underway to expand market reach.
The most recent analyst rating on (CTOR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
Citius Oncology’s stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Citius Oncology, a subsidiary of Citius Pharmaceuticals, operates in the oncology sector with a focus on developing and commercializing cancer therapies. The company is preparing to launch LYMPHIR™, an FDA-approved immunotherapy for cutaneous T-cell lymphoma (CTCL), marking its transition from a development-stage enterprise to a commercial organization.
Average Trading Volume: 1,494,968
Technical Sentiment Signal: Hold
Current Market Cap: $99.46M
For an in-depth examination of CTOR stock, go to TipRanks’ Overview page.